Volume 22 Issue 5
May  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(5): 772-775
ZHOU Taomei, LIU Siyu, DAI Mugen. Diagnostic performance of serum pepsinogen in asymptomatic patients with persistent Helicobacter pylori infection[J]. Chinese Journal of General Practice, 2024, 22(5): 772-775. doi: 10.16766/j.cnki.issn.1674-4152.003500
Citation: ZHOU Taomei, LIU Siyu, DAI Mugen. Diagnostic performance of serum pepsinogen in asymptomatic patients with persistent Helicobacter pylori infection[J]. Chinese Journal of General Practice, 2024, 22(5): 772-775. doi: 10.16766/j.cnki.issn.1674-4152.003500
shu

Diagnostic performance of serum pepsinogen in asymptomatic patients with persistent Helicobacter pylori infection

doi: 10.16766/j.cnki.issn.1674-4152.003500
  • 1.

    Department of Gastroenterology, the Fifth Hospital Affiliated to Wenzhou Medical University, Lishui, Zhejiang 323000, China

Funds:

 2022ZB406

  • Received Date: 2023-09-26
    Available Online: 2024-07-20
    Abstract
  •   Objective  This study aimed to explore serum pepsinogen (PG) detection results in asymptomatic patients with persistent Helicobacter pylori (H. pylori) infection, with the potential application of serum PG detection for screening high-risk gastric cancer patients.  Methods  A total of 583 patients who underwent gastroscopy at the Fifth Affiliated Hospital of Wenzhou Medical University between January 2021 and December 2022 were included in this study. Among them, asymptomatic individuals who underwent 13C urea breath test (13C-UBT) and serum PG detection for cancer screening on the same day of gastroscopy were enrolled.  Results  Out of the 583 subjects, 206 patients (35.33%) tested positive for the 13C-UBT, exhibiting higher levels of serum PG Ⅰ and PG Ⅱ compared to the uninfected population. Additionally, their PG Ⅰ/Ⅱ ratios were lower than those observed in the uninfected population (P<0.05). Univariate logistic regression analysis showed that H. pylori infection was associated with PG Ⅰ, PG Ⅱ, and PG Ⅰ/Ⅱ ratio (P<0.05), as well as age and diabetes (P<0.001). In the multivariate analysis, only serum PG Ⅱ (OR=1.293, 95% CI: 0.932-2.085, P<0.001) and PG Ⅰ/Ⅱ ratio (OR=0.594, 95% CI: 0.343-0.978, P<0.001) remained as independent risk factors for persistent H. pylori infection. A serum PG Ⅱ level > 13.59 μg/L (AUC=0.934, sensitivity 87.5%, specificity 91.7%) and a PG Ⅰ/Ⅱ ratio<4.85 (AUC=0.890, sensitivity 86.8%, specificity 81.6%) are associated with H. pylori infection. Further, the PG Ⅰ/Ⅱ ratio showed an inverse correlation with age (r=-0.167, P=0.041). Notably, the cut-off value of PG Ⅰ/Ⅱ ratio in elderly subjects aged 50 (<4.27; AUC=0.865, sensitivity 80.7%, specificity 88.2%) was lower than that in young subjects under 50 (<4.85; AUC=0.903, sensitivity 87.4%, specificity 82.9%).  Conclusion  Serum PG Ⅱ level > 13.59 ng/mL, PG Ⅰ/Ⅱ ratio<4.85 indicates persistent infection in asymptomatic subjects, and consideration should be given to conducting Helicobacter pylori 13C-UBT confirmation testing. Compared to young subjects, elderly subjects aged ≥ 50 years require stricter standards (PG Ⅰ/Ⅱ ratio<4.27) to detect persistent infections.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    LIOU J M, MALFERTHEINER P, LEE Y C, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus[J]. Gut, 2020, 69(12): 2093-2112. doi: 10.1136/gutjnl-2020-322368
    [2]
    SABBAGH P, MOHAMMADNIA-AFROUZI M, JAVANIAN M, et al. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(1): 55-66. doi: 10.1007/s10096-018-3414-4
    [3]
    MLADENOVA I. Clinical relevance of Helicobacter pylori infection[J]. J Clin Med, 2021, 10(16): 3473. doi: 10.3390/jcm10163473
    [4]
    KWAK M S, CHUNG G E, CHUNG S J, et al. Predicting the development of gastric neoplasms in a healthcare cohort by combining Helicobacter pylori antibodies and serum pepsinogen: a 5-year longitudinal study[J]. Gastroenterol Res Pract, 2018: 8796165. DOI: 10.1155/2018/8796165.
    [5]
    SHAN J, LEI H J, SHI W, et al. High serum pepsinogen Ⅰ and beta Helicobacter pylori infection are risk factors for aspirin-induced gastroduodenal injury[J]. Dig Dis, 2018, 36(1): 66-71. doi: 10.1159/000477203
    [6]
    卢光荣, 何柏琪, 林颖, 等. 根除幽门螺旋杆菌感染对不同程度胃黏膜肠上皮化生患者病理学改变的前瞻性研究[J]. 中华全科医学, 2019, 17(4): 571-573. doi: 10.16766/j.cnki.issn.1674-4152.000737

    LU G R, HE B Q, LIN Y, et al. A prospective study on pathological changes in patients with different degrees of gastric mucosal intestinal metaplasia after eradicating Helicobacter pylori infection[J]. Chinese Journal of General Practice, 2019, 17(4): 571-573. doi: 10.16766/j.cnki.issn.1674-4152.000737
    [7]
    BAEK S M, KIM N, KWON Y J, et al. Role of serum pepsinogen Ⅱ and Helicobacter pylori status in the detection of diffuse-type early gastric cancer in young individuals in South Korea[J]. Gut Liver, 2020, 14(4): 439-449. doi: 10.5009/gnl19091
    [8]
    TRIVANOVIC D, PLESTINA S, HONOVIC L, et al. Gastric cancer detection using the serum pepsinogen test method[J]. Tumori, 2022, 108(4): 386-391. doi: 10.1177/03008916211014961
    [9]
    DI MARIO F, CRAFA P, BARCHI A, et al. Pepsinogen Ⅱ in gastritis and Helicobacter pylori infection[J]. Helicobacter, 2022, 27(2): e12872. DOI: 10.1111/hel.12872.
    [10]
    GRAVINA A G, PRIADKO K, CIAMARRA P, et al. Extra-gastric manifestations of Helicobacter pylori Infection[J]. J Clin Med, 2020, 9(12): 3887. doi: 10.3390/jcm9123887
    [11]
    YUAN L, ZHAO J B, ZHOU Y L, et al. Type Ⅰ and type Ⅱ Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area[J]. World J Gastroenterol, 2020, 26(25): 3673-3685. doi: 10.3748/wjg.v26.i25.3673
    [12]
    EL HAFA F, WANG T P, NDIFOR V M, et al. Association between Helicobacter pylori antibodies determined by multiplex serology and gastric cancer risk: a meta-analysis[J]. Helicobacter, 2022, 27(3): e12881. DOI: 10.1111/hel.12881.
    [13]
    DING S Z, DU Y Q, LU H, et al. Chinese Consensus Report on family-based Helicobacter pylori infection control and management (2021 Edition)[J]. Gut, 2022, 71(2): 238-253. doi: 10.1136/gutjnl-2021-325630
    [14]
    TRIVANOVIC D, PLESTINA S, HONOVIC L, et al. Gastric cancer detection using the serum pepsinogen test method[J]. Tumori, 2022, 108(4): 386-391. doi: 10.1177/03008916211014961
    [15]
    BAEK S M, KIM N, KWON Y J, et al. Role of serum Pepsinogen Ⅱ and Helicobacter pylori status in the detection of diffuse-type early gastric cancer in young individuals in South Korea[J]. Gut Liver, 2020, 14(4): 439-449. doi: 10.5009/gnl19091
    [16]
    SHENG C, SUN L P, LYU Z Y, et al. Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals[J]. Helicobacter, 2023, 28(3): e12966. DOI: 10.1111/hel.12966.
    [17]
    LEE H S, JEON S W, NOMURA S, et al. Screening biomarker as an alternative to endoscopy for the detection of early gastric cancer: the combination of serum trefoil factor family 3 and pepsinogen[J]. Gastroenterol Res Pract, 2018: 1024074. DOI: 10.1155/2018/1024074.
    [18]
    SONG Z Q, CHEN Y, LU H, et al. Diagnosis and treatment of Helicobacter pylori infection by physicians in China: a nationwide cross-sectional study[J]. Helicobacter, 2022, 27(3): e12889. DOI: 10.1111/hel.12889.
    [19]
    中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组, 全国幽门螺杆菌研究协作组. 第五次全国幽门螺杆菌感染处理共识报告[J]. 中华内科杂志, 2017, 56(7): 532-545. doi: 10.3760/cma.j.issn.0578-1426.2017.07.014

    Chinese Medical Association Gastroenterology Division Pylori and Peptic Ulcer Study Group, National Collaborative Group on Helicobacter Pylori Research. The Fifth Chinese national consensus report on the management of Helicobacter pylori infection[J]. Chinese Journal of Internal Medicine, 2017, 56(7): 532-545. doi: 10.3760/cma.j.issn.0578-1426.2017.07.014
    [20]
    HAJ-SHEYKHOLESLAMI A, RAKHSHANI N, AMIRZARGAR A, et al. Serum pepsinogen Ⅰ, pepsinogen Ⅱ, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis[J]. Clin Gastroenterol Hepatol, 2008, 6(2): 174-179. doi: 10.1016/j.cgh.2007.11.016
    [21]
    杨德红, 朱传会, 张晓勇, 等. 南京市建邺区60~80岁老年人群幽门螺旋杆菌感染及与胃蛋白酶原相关性分析[J]. 公共卫生与预防医学, 2022, 33(3): 138-141. doi: 10.3969/j.issn.1006-2483.2022.03.032

    YANG D H, ZHU C H, ZHANG X Y, et al. Analysis of helicobacter pylori infection and its correlation with pepsinogen in the elderly population aged 60-80 in Jianye District, Nanjing[J]. Public Health and Preventive Medicine, 2022, 33(3): 138-141. doi: 10.3969/j.issn.1006-2483.2022.03.032
    [22]
    金丽雯, 徐继. 血清PG、G-17联合Hp水平评估胃癌的临床分析[J]. 检验医学与临床, 2022, 19(1): 109-111. doi: 10.3969/j.issn.1672-9455.2022.01.029

    JIN L W, XU J. Clinical analysis of serum PG, G-17 combined with Hp levels in evaluating gastric cancer[J]. Journal of Laboratory Medicine and Clinical Sciences, 2022, 19(1): 109-111. doi: 10.3969/j.issn.1672-9455.2022.01.029
    [23]
    YU H, LIU Y, JIANG S J, et al. Serum pepsinogen Ⅱ levels are doubled with Helicobacter pylori infection in an asymptomatic population of 40, 383 Chinese subjects[J]. Medicine (Baltimore), 2021, 100(27): e26562. DOI: 10.1097/MD.0000000000026562.
    [24]
    CHO J H, JEON S R, JIN S Y, et al. Analysis of factors associated with recovery of the serum pepsinogen ratio after Helicobacter pylori eradication: a long-term follow-up study in Korea[J]. Scand J Gastroenterol, 2019, 54(11): 1306-1314. doi: 10.1080/00365521.2019.1686058
    [25]
    陈薛霖, 侯运萌, 周芳, 等. 慢性胃炎患者幽门螺杆菌感染的影响因素及对胃蛋白酶原和胃内菌群的影响[J]. 中国卫生工程学, 2022, 21(5): 857-859, 862.

    CHEN X L, HOU Y M, ZHOU F, et al. The influencing factors of Helicobacter pylori infection in patients with chronic gastritis and its impact on pepsinogen and gastric microbiota[J]. China Health Engineering, 2022, 21(5): 857-859, 862.
    [26]
    ZHOU J P, LIU C H, LIU B W, et al. Association of serum pepsinogens and gastrin-17 with Helicobacter pylori infection assessed by urea breath test[J]. Front Cell Infect Microbiol, 2022, 12: 980399. DOI: 10.3389/fcimb.2022.980399.
    [27]
    杜梅玲, 楚艳, 张自强, 等. 萎缩性与非萎缩性胃炎患者之间幽门螺杆菌根除率的差异性研究[J]. 中华全科医学, 2023, 21(6): 920-923, 957. doi: 10.16766/j.cnki.issn.1674-4152.003015

    DU M L, CHU Y, ZHANG Z Q, et al. Differences in Helicobacter pylori eradication rates between patients with atrophic and non atrophic gastritis[J]. Chinese Journal of General Practice, 2023, 21(6): 920-923, 957. doi: 10.16766/j.cnki.issn.1674-4152.003015
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (89) PDF downloads(3) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return